Trading Report: Today, Aptose Biosciences Inc. (APTO) Receives $8.00 Consensus Target Price from Brokerages

Today, Aptose Biosciences Inc. (APTO) Receives $8.00 Consensus Target Price from Brokerages

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) has earned an average recommendation of “Buy” from the six research firms that are covering the firm. Six research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $8.00.

APTO has been the topic of several recent analyst reports. RBC Capital Markets reiterated an “outperform” rating on shares of Aptose Biosciences in a research note on Tuesday, September 13th. Roth Capital reiterated a “buy” rating and set a $8.00 target price on shares of Aptose Biosciences in a research note on Friday, October 14th. Zacks Investment Research upgraded Aptose Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 11th. Royal Bank Of Canada cut their target price on Aptose Biosciences from $18.00 to $12.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 16th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $7.00 target price on shares of Aptose Biosciences in a research note on Saturday, October 15th.

Aptose Biosciences (NASDAQ:APTO) opened at 0.9671 on Wednesday. The company’s 50-day moving average price is $1.44 and its 200 day moving average price is $2.19. Aptose Biosciences has a 52-week low of $0.83 and a 52-week high of $4.33. The stock’s market capitalization is $13.01 million.

An institutional investor recently bought a new position in Aptose Biosciences stock. Bank of Montreal Can purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to its most recent disclosure with the SEC. The fund purchased 52,624 shares of the company’s stock, valued at approximately $128,000. Bank of Montreal Can owned approximately 0.43% of Aptose Biosciences as of its most recent filing with the SEC. Hedge funds and other institutional investors own 19.20% of the company’s stock.

Related posts

Leave a Comment